Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma

Oncologist

Volumn 19, Issue 9, 2014, Pages 915-916

  Agarwal, Neeraj ^a   Apolo, Andrea B ^b   Tsao, Che Kai ^c   Lee, Karen M ^c   Godbold, James H ^c   Soto, Rothschild ^c   Poole, Austin ^a   Gimpel Tetra, Kiev ^c   Lowe, Nancy ^c   Oh, William K ^c   Galsky, Matthew D ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; LENALIDOMIDE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; THALIDOMIDE;

ARTICLE; CLINICAL ARTICLE; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TRANSITIONAL CELL CARCINOMA; ADVERSE DRUG REACTION; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; UROTHELIUM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DEOXYCYTIDINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; THALIDOMIDE; UROTHELIUM;

EID: 84906984044     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0153     Document Type: Article

References (0)